ARTICLE | Regulation
Seek, but not find
December 8, 2008 8:00 AM UTC
In voting to recommend approval of Uloric febuxostat to treat chronic gout, FDA's Arthritis Advisory Committee concluded that its benefits trumped an ambiguous cardiovascular safety signal.
The committee voted 12-0 with one abstention on Nov. 24 to recommend approval of Uloric, a non-purine inhibitor of xanthine oxidase from Takeda Pharmaceutical Co. Ltd...